Cite
APA Citation
Badibouidi, F., Dupont, L., Benchaabane, M., & Loutski, S. (n.d.). 4CPS-072 Comparison of immune checkpoint inhibitors (nivolumab, pembrolizumab, atézolizumab and durvalumab) in the treatment of non-small cell lung cancer: tolerance and financial impact. European journal of hospital pharmacy, 27, A81. http://access.bl.uk/ark:/81055/vdc_100137792709.0x000004